An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report

ABSTRACT Background Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non‐small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combinatio...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Li Wang, Jiaqi Wu, Ping Shao, Wuping Bao, Lin Mao, Zhendong Pan, Aihua Bao, Min Zhang, Zhenghua Wu, Guorong Fan
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2025-06-01
Ráidu:	Cancer Reports
Fáttát:	anti‐angiogenic agents camrelizumab case report KRAS mutations lung adenocarcinoma
Liŋkkat:	https://doi.org/10.1002/cnr2.70186
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!